Percutaneous versus Transjugular Random Renal Biopsy in High-Risk Patients: Comparison of Outcomes

Monday, March 31, 2025

4:03 PM – 4:12 PM CT

Location: Music City Center, 207 CD

Presenting Author(s)

Peyton Hopkins, MD

Research Fellow
LSUHSC - New Orleans, United States

Author/Co-author(s)

KG

Katelyn Gill, BS

Medical Student
LSUHSC - New Orleans, United States
Dan Laney, MD

Assistant Professor - Clinical
LSU Health New Orleans, United States
RM

Rajesh Mohandas, MD

Chief- Nephrology and Hypertension
LSUHSC - New Orleans, United States
HL

Hieu Le, MD

Radiology Resident
LSUHSC - New Orleans, United States
HF

Hector Ferral, MD, FSIR (he/him/his)

Vice-Chairman of Research
Louisiana State University, New Orleans, United States

Purpose:

The purpose of this retrospective study was to compare outcomes between percutaneous random renal biopsy (PRRB) versus Transjugular Random Renal Biopsy (TJRRB) in high bleeding risk patients.

Materials and Methods:

This is a retrospective, IRB approved and HIPPA compliant study. At our institution, TJRRB is recommended for patients with morbid obesity and a calculated bleeding risk score (BRS) >15. The records of all patients who underwent a PRRB between April 2020 and June 2024 were reviewed and a selected cohort of patients with a BRS >15 was identified and compared to patients who underwent transjugular random renal biopsy (TJRRB) during the same time period. Patient risk factors, technical success, diagnostic yield and complication rates were compared. Univariate data analyses were performed with p< 0.05 considered to be statistically significant.

Results:

A total of 21 patients underwent TJRRB and 21 PRRB high risk patients were identified. Patient demographics and results are summarized in Table 1. Patients undergoing PRRB were older and patients undergoing TJRRB had higher mean BMI. Biopsy diagnostic rate and number of glomeruli per biopsy were similar. Major bleeding complications were identical (4.76%). There were no deaths related to either biopsy technique.

Conclusion:

This study showed that PRRB and TJRRB are comparable in safety and diagnostic yield in patients with high bleeding risk. BMI >35 may be the main indication for TJRRB.